Cargando…

Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line

BACKGROUND: Cancer cell migration is fundamentally required for breast tumour invasion and metastasis. The insulin-like growth factor 1 tyrosine kinase receptor (IGF-1R) and the chemokine G-protein coupled receptor, CXCR4 have been shown to play an important role in breast cancer metastasis. Our pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Meizhi, Klingler-Hoffmann, Manuela, Brazzatti, Julie A, Forbes, Briony, Akekawatchai, Chareeporn, Hoffmann, Peter, McColl, Shaun R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564858/
https://www.ncbi.nlm.nih.gov/pubmed/23320409
http://dx.doi.org/10.1186/1477-5956-11-4
_version_ 1782258372371808256
author Niu, Meizhi
Klingler-Hoffmann, Manuela
Brazzatti, Julie A
Forbes, Briony
Akekawatchai, Chareeporn
Hoffmann, Peter
McColl, Shaun R
author_facet Niu, Meizhi
Klingler-Hoffmann, Manuela
Brazzatti, Julie A
Forbes, Briony
Akekawatchai, Chareeporn
Hoffmann, Peter
McColl, Shaun R
author_sort Niu, Meizhi
collection PubMed
description BACKGROUND: Cancer cell migration is fundamentally required for breast tumour invasion and metastasis. The insulin-like growth factor 1 tyrosine kinase receptor (IGF-1R) and the chemokine G-protein coupled receptor, CXCR4 have been shown to play an important role in breast cancer metastasis. Our previous study has shown that IGF-1R can transactivate CXCR4 via a physical association in the human MDA-MB-231 metastatic breast cancer cell line and that this plays a key role in IGF-I-induced migration of these cells. In the present study we used pharmacological inhibition and RNAi to identify PI3Kγ as an important migration signalling molecule downstream of receptor transactivation in MDA-MB-231 cells. To identify PI3Kγ-regulated proteins upon transactivation of CXCR4 by IGF-I, we undertook a comparative proteomics approach using 2-D- Fluorescence Difference Gel Electrophoresis (DIGE) and identified the proteins by mass spectrometry. RESULTS: These experiments identified eukaryotic elongation factor 2 (eEF2) as a novel downstream target of PI3Kγ after activation of the IGF-1R-CXCR4 heterodimer by IGF-I. Further analysis demonstrated that eEF2 is phosphorylated in MDA-MB-231 cells in response to IGF-I and that this is dependent on PI3Kγ activity. CONCLUSIONS: Our data imply a novel role for PI3Kγ in facilitating cell migration by regulating phosphorylation of eEF2.
format Online
Article
Text
id pubmed-3564858
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35648582013-02-08 Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line Niu, Meizhi Klingler-Hoffmann, Manuela Brazzatti, Julie A Forbes, Briony Akekawatchai, Chareeporn Hoffmann, Peter McColl, Shaun R Proteome Sci Research BACKGROUND: Cancer cell migration is fundamentally required for breast tumour invasion and metastasis. The insulin-like growth factor 1 tyrosine kinase receptor (IGF-1R) and the chemokine G-protein coupled receptor, CXCR4 have been shown to play an important role in breast cancer metastasis. Our previous study has shown that IGF-1R can transactivate CXCR4 via a physical association in the human MDA-MB-231 metastatic breast cancer cell line and that this plays a key role in IGF-I-induced migration of these cells. In the present study we used pharmacological inhibition and RNAi to identify PI3Kγ as an important migration signalling molecule downstream of receptor transactivation in MDA-MB-231 cells. To identify PI3Kγ-regulated proteins upon transactivation of CXCR4 by IGF-I, we undertook a comparative proteomics approach using 2-D- Fluorescence Difference Gel Electrophoresis (DIGE) and identified the proteins by mass spectrometry. RESULTS: These experiments identified eukaryotic elongation factor 2 (eEF2) as a novel downstream target of PI3Kγ after activation of the IGF-1R-CXCR4 heterodimer by IGF-I. Further analysis demonstrated that eEF2 is phosphorylated in MDA-MB-231 cells in response to IGF-I and that this is dependent on PI3Kγ activity. CONCLUSIONS: Our data imply a novel role for PI3Kγ in facilitating cell migration by regulating phosphorylation of eEF2. BioMed Central 2013-01-15 /pmc/articles/PMC3564858/ /pubmed/23320409 http://dx.doi.org/10.1186/1477-5956-11-4 Text en Copyright ©2013 Niu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Niu, Meizhi
Klingler-Hoffmann, Manuela
Brazzatti, Julie A
Forbes, Briony
Akekawatchai, Chareeporn
Hoffmann, Peter
McColl, Shaun R
Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line
title Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line
title_full Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line
title_fullStr Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line
title_full_unstemmed Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line
title_short Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line
title_sort comparative proteomic analysis implicates eef2 as a novel target of pi3kγ in the mda-mb-231 metastatic breast cancer cell line
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564858/
https://www.ncbi.nlm.nih.gov/pubmed/23320409
http://dx.doi.org/10.1186/1477-5956-11-4
work_keys_str_mv AT niumeizhi comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline
AT klinglerhoffmannmanuela comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline
AT brazzattijuliea comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline
AT forbesbriony comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline
AT akekawatchaichareeporn comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline
AT hoffmannpeter comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline
AT mccollshaunr comparativeproteomicanalysisimplicateseef2asanoveltargetofpi3kginthemdamb231metastaticbreastcancercellline